Amphion Innovations plc
IP Licensing

London and New York, 24 September 2010 – Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces that its wholly owned subsidiary, DataTern, Inc., has settled certain pending patent infringement litigation over its U.S. Patents 6,101,502 and 5,937,402, generating total revenues of $500,000.

DataTern has signed 22 licenses of these patents since June 2008, generating total revenues of approximately $14 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, airline, e-commerce, and software industries.

DataTern, Inc., was originally established in order to commercialise selected intellectual property opportunities in partnership with Amphion’s Partner Companies. As part of the licensing programme described above, DataTern offers to license all parties in all industries under these patents.

For further information please contact:
Amphion Innovations plc
Charlie Morgan
+44 779 953 6043

Cardew Group
Tim Robertson/ Jamie Milton
+44 20 7930 0777

Charles Stanley (Nominated Adviser)
Mark Taylor
+44 20 7149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number that grows rapidly each year.

On the web: